Praxis Precision Medicines announced a collaboration and license with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide and made an equity investment in Remagine.
Key Highlights:
- Entered research collaboration and license agreement with Remagine to apply its iontophoretic transdermal platform to ulixacaltamide for essential tremor.
- Transdermal patch aims for precise, multi-day active dosing to broaden patient reach and complement Praxis’s lead oral program.
- Company made an equity investment in Remagine, signaling commitment to rapidly advance the transdermal program.
- Praxis expects the transdermal option to strengthen competitive positioning and extend long-term franchise value.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.